FDA PDUFA review goal date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)Assuming ...

Milestone Pharmaceuticals Inc. announced that the FDA has set a PDUFA review goal date of March 27, 2025, for its nasal spray CARDAMYST™ (etripamil), aimed at treating Paroxysmal ...

The study will use the patient self-administration 70-mg repeat-dose regimen, of etripamil nasal spray, outside of the medically supervised setting, similar to that used in the PSVT development ...

The study will use the patient self-administration 70-mg repeat-dose regimen, of etripamil nasal spray, outside of the medically supervised setting, similar to that used in the PSVT development ...

Etripamil is Milestone's lead investigational product. It is a novel calcium channel blocker nasal spray under clinical development for frequent and often highly symptomatic episodes of PSVT and ...

One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

The study will use the patient self-administration 70-mg repeat-dose regimen, of etripamil nasal spray, outside of the medically supervised setting, similar to that used in the PSVT development ...

Nasal anti-CD3 spray reduces traumatic brain injury in mice, a potential breakthrough for TBI treatment. Read now.

Chronic rhinosinusitis with nasal polyps presents a substantial clinical burden, affecting nasal airflow, olfactory function, ...

Keep reading to learn how nasal sumatriptan works, who could benefit, and how it compares with other types of sumatriptan.

The asthma medication reduces congestion in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps in a ...